Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.

Autor: Shah R; Division of Cancer Medicine The University of Texas MD Anderson Cancer Center.; Department of Medicine Vanderbilt University Medical Center., Murphy D; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Logue M; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Jerkins J; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Jallouk A; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Adetola K; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Oluwole O; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Jayani R; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Biltibo E; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Kim TK; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Sengsayadeth S; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Chinratanalab W; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Kitko C; Division of Hematology/Oncology, Department of Pediatrics Vanderbilt University Medical Center., Savani B; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center., Dholaria B; Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center.

Publikováno v: Clinical hematology international [Clin Hematol Int] 2024 Oct 21; Vol. 6 (4), pp. 74-88. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).

The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?

Autor: Knight E T; Cancer and Blood Disorders Center Seattle Children's Hospital., Oluwole O; Medicine Hematology and Oncology, Vanderbilt University Medical Center., Kitko C; Pediatrics Vanderbilt University Medical Center.

Publikováno v: Clinical hematology international [Clin Hematol Int] 2024 Mar 13; Vol. 6 (1), pp. 96-115. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).

Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.

Autor: Lee CJ; The University of Utah Transplant and Cellular Therapy Program, Salt Lake City, Utah. Electronic address: Catherine.lee@hci.utah.edu., Wang T; Division of Biostatistics, Institute for Heath and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Chen K; Division of Biostatistics, Institute for Heath and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Arora M; Division of Hematology, Oncology and Transplant, University of Minnesota Medical Center, Minneapolis, Minnesota., Brazauskas R; Division of Biostatistics, Institute for Heath and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Spellman SR; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota., Kitko C; Department of Pediatrics, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., MacMillan ML; Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota., Pidala JA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Auletta JJ; Department of Hematology/Oncology/BMT and Infectious Diseases, Nationwide Children's Hospital, Ohio State University, Columbus, Ohio., Badawy SM; Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Evanston, Illinois., Bhatt N; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Bhatt VR; Section of Hematology, University of Nebraska, Omaha, Nebraska., Cahn JY; Department of Hematology, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France., DeFilipp Z; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Diaz MA; Hospital Niño Jesus, Madrid, Spain., Farhadfar N; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida., Gadalla S; Clinical Genetics Branch, National Cancer Institute, Rockville, Maryland., Gale RP; Haematology Section, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom., Hashem H; Department of Pediatrics, Pediatric Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan., Hashmi S; Department of Internal Medicine, Mayo Clinic, Minnesota; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates., Hematti P; Section of Hematology/Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin., Hong S; Department of Hematology and Oncology, University Hospitals, Case Western Reserve University, Cleveland, Ohio., Hossain NM; Loyola University Chicago-Stritch School of Medicine, Maywood, Illinois., Inamoto Y; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan., Lekakis LJ; Sylvester Cancer Center, University of Miami, Miami, Florida., Modi D; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Patel S; The University of Utah Transplant and Cellular Therapy Program, Salt Lake City, Utah., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee., Solomon S; Northside Hospital Cancer Institute, Atlanta, Georgia., Couriel DR; The University of Utah Transplant and Cellular Therapy Program, Salt Lake City, Utah.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2022 Oct; Vol. 28 (10), pp. 712.e1-712.e8. Date of Electronic Publication: 2022 Jul 18.

Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation.

Autor: Patel A; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: ameet.patel@vumc.org., Wilkerson K; Department of Hematology/Oncology, Vanderbilt-Meharry Sickle Cell Center of Excellence, Vanderbilt University Medical Center, Nashville, Tennessee., Chen H; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee., Sharma D; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Hematology/Oncology, Vanderbilt-Meharry Sickle Cell Center of Excellence, Vanderbilt University Medical Center, Nashville, Tennessee., Byrne M; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Green J; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Sengsayadeth S; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Hematology/Stem Cell Transplant, Veteran Hospital Administration, Nashville, Tennessee., Dholaria B; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Savani B; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Hematology/Stem Cell Transplant, Veteran Hospital Administration, Nashville, Tennessee., Chinratanalab W; Department of Hematology/Stem Cell Transplant, Veteran Hospital Administration, Nashville, Tennessee., Jayani R; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Gatwood K; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee., Engelhardt BG; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Kitko C; Division of Hematology/Oncology and Bone Marrow Transplant, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Connelly J; Division of Hematology/Oncology and Bone Marrow Transplant, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Kassim A; Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Hematology/Oncology, Vanderbilt-Meharry Sickle Cell Center of Excellence, Vanderbilt University Medical Center, Nashville, Tennessee.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2022 May; Vol. 28 (5), pp. 277.e1-277.e6. Date of Electronic Publication: 2022 Feb 15.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.

Autor: Pidala J; Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Electronic address: joseph.pidala@moffitt.org., Kitko C; Division of Pediatric Hematology/Oncology, Dpeartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee., Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Carpenter P; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Cuvelier GDE; Cancer Care Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada., Holtan S; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota., Flowers ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Cutler C; Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, Massachusetts., Jagasia M; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Palmer J; Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope, Duarte, California., Randolph T; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Levine JE; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Dignan F; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Schoemans H; Department of Hematology, University Hospitals Leuven and Department of Public Health, KU Leuven, Leuven, Belgium., Tkaczyk E; Department of Veterans Affairs and Departments of Dermatology and Biomedical Engineering, Vanderbilt University Medical Center, Nashville, Tennessee., Farhadfar N; Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, Florida., Lawitschka A; Stem Cell Transplantation Unit, St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria., Schultz KR; Pediatric Hematology/Oncology/BMT, BC Children's Hospital, Vancouver, British Columbia, Canada., Martin PJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Sarantopoulos S; Division of Hematological Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University Department of Medicine, Durham, North Carolina., Inamoto Y; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan., Socie G; Hematology and Bone Marrow Transplant Department, AP-HP Saint Louis Hospital and University of Paris, Paris, France., Wolff D; Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany., Blazar B; Department of Pediatrics, Division of Blood & Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota., Greinix H; Clinical Division of Hematology, Medical University of Graz, Graz, Austria., Paczesny S; Department of Microbiology and Immunology and Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina., Pavletic S; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Hill G; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2021 Aug; Vol. 27 (8), pp. 632-641. Date of Electronic Publication: 2021 Apr 06.